CCEL

Add to Watchlist

Advanced Chart

0.000

0.000(0.000%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

5.6474

Open

5.610

VWAP

5.59

Vol

8.18K

Mkt Cap

44.57M

Low

5.3801

Amount

45.67K

EV/EBITDA(TTM)

10.31

Total Shares

8.10M

50.39M

EV/OCF(TTM)

6.88

P/S(TTM)

1.43

Cryo-Cell International, Inc. is a cord blood banking company. The Company operates through three segments: cellular processing and cryogenic storage for family use, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells; manufacture of PrepaCyte CB Processing System (PrepaCyte CB) units, the processing technology used to process umbilical cord blood stem cells, and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The Company stores approximately 500,000 cord blood and cord tissue specimens. The specimens are stored in commercially available cryogenic storage units at this technologically and operationally advanced facility. The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

8.03M

+0.06%

-0.040

-84.28%

8.10M

+0.41%

-0.040

-127.97%

8.04M

-0.02%

-0.040

-141.61%

Estimates Revision

The market is revising Upward the revenue expectations for Cryo-Cell International, Inc. (CCEL) for FY2025, with the revenue forecasts being adjusted by 0.27% over the past three months. During the same period, the stock price has changed by -27.62%.

Revenue Estimates for FY2025

Revise Upward

+0.27%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-25%

In Past 3 Month

Stock Price

Go Down

-27.62%

In Past 3 Month

1 Analyst Rating

54.13% Upside

Wall Street analysts forecast CCEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CCEL is 8.50 USD with a low forecast of 8.50 USD and a high forecast of 8.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

54.13% Upside

Current: 5.515

Low

8.50

Averages

8.50

High

8.50

54.13% Upside

Current: 5.515

Low

8.50

Averages

8.50

High

8.50

Maxim Group

Allen Klee

Strong Buy

Maintains

$9 → $8.5

2025-03-04

Reason

Maxim Group

Allen Klee

Price Target

$9 → $8.5

2025-03-04

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Cryo-Cell International Inc (CCEL.A) is -37.47, compared to its 5-year average forward P/E of 24.58. For a more detailed relative valuation and DCF analysis to assess Cryo-Cell International Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

24.58

Current PE

-37.47

Overvalued PE

122.88

Undervalued PE

-73.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

11.65

Current EV/EBITDA

14.94

Overvalued EV/EBITDA

21.69

Undervalued EV/EBITDA

1.60

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

1.19

Current PS

1.41

Overvalued PS

2.09

Undervalued PS

0.28